Lung cancer is the leading cause of death worldwide. Its overall survival rate has improved only slightly, and surgery, radiotherapy, and chemotherapy remain the mainstays of current treatment. Therapies with novel targeted agents are currently under active investigation in all settings of treatment including chemoprevention, defined as the use of natural or synthetic agents to interrupt the process of carcinogenesis and to prevent or delay tumor occurrence. Thus, chemoprevention describes the collaborative efforts of researchers in basic science and clinical settings who study the biology of lung cancer with the hope of uncovering new mechanisms of treatment. Because lung cancer has become an increasingly difficult problem to treat with standard therapies, chemopreventive strategies have been developed. Small molecule compounds that target specific receptors or mutations will play an increasingly significant role in treatment of lung cancer because the side effect profiles of such agents are tolerable and they may be more effective than other treatments.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Adler I: Primary Malignant Growths of the Lung and Bronchi. New York: Longmans, Green; 1912.Google Scholar
- 3.Ochsner A, Debakey M: Carcinoma of the lung. Arch Surgery 1940, Dec:209–258.Google Scholar
- 24.Yellin A, Hill LR, Benfield JR: Bronchogenic carcinoma associated with upper aerodigestive cancers. J Thoracic Cardiovasc Surg 1986, 91:674–683.Google Scholar
- 33.Warren S, Gates O: Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932, 16:1358–1403.Google Scholar
- 37.Khuri FR, Lee JJ, Winn RJ, et al.: Interim analysis of randomized chemoprevention trial of HNSCC [abstract]. Proc ASCO 1999, 18:1503.Google Scholar
- 38.Kim ES, Khuri FR, Lee JJ, et al.: Second primary tumor incidence related to primary index tumor and smoking status in a randomized chemoprevention study of head and neck squamous cell cancer [abstract]. Proc ASCO 2000, 19:1642.Google Scholar
- 40.Khuri FR, Kim ES, Lee JJ, et al.: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the Head and Neck Retinoid Chemoprevention Trial. Cancer Epidemiol Biomarkers Prev 2001, 10:823–829. This report from the Head and Neck Retinoid Chemoprevention Second Primary Tumor Trial reflects the first large-scale chemoprevention study evaluating smoking status and its impact on the development of SPTs.PubMedGoogle Scholar
- 41.van Zandwijk N, Dalesio O, Pastorino U, et al.: EUROSCAN: a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000, 92:977–986. Another trial that did not show significant activity of chemoprevention agents in patients with lung or head and neck cancer.PubMedCrossRefGoogle Scholar
- 42.Lippman SM, Lee JJ, Karp DD, et al.: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 2001, 93:605–618. This trial demonstrated no beneficial effect of isotretinoin in patients with early-stage lung cancer.PubMedCrossRefGoogle Scholar
- 44.Shin DM, Khuri FR, Murphy B, et al.: Combined interferonalfa, 13 cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001, 19:3010–3017. This trial demonstrated that biochemoprevention is a feasible and effective approach for locally advanced disease.PubMedGoogle Scholar